Pharmacology of low molecular weight heparins

Emergency Medicine Clinics of North America

Volumn 19, Issue 4, 2001, Pages 1025-1049

  Kleinschmidt, Kurt ^a   Charles, Ronald ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

BLEEDING; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 0035202877     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8627(05)70233-9     Document Type: Article

References (92)

1. Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep venous thrombosis
2. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip replacement
3. The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig
4. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction
5. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-wave myocardial infarction
6. Optimal management of pregnant women with acute venous thromboembolism
7. Conjecture and refutations on the mode of action of heparins
8. Low molecular weight heparins
9. A pharmacokinetic study of dalteparin (Fragmin) in late pregnancy
10. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
11. Delayed elimination of enoxaparin in patients with chronic renal insufficiency
12. Effect of low-molecular-weight heparin on serum potassium
13. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
14. Prevention of venous thromboembolism
15. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
16. Pharmacokinetic profile of a low-molecular-weight heparin (Reviparin) in pregnant patients: A prospective cohort study
17. Randomized, placebo-controlled trial anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis
18. Physician orders for initiating enoxaparin therapy
19. Nadroparin versus dalteparin anti- coagulation in high-volume, continuous venovenous hemofiltration: A double-blind, randomized, crossover study
20. Structural features and bleeding activity of commercial low molecular weight heparins: Neutralization by ATP and protamine
21. The use of low molecular weight heparin in pediatric patients: A prospective cohort study
22. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
23. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
24. Low-molecular-weight heparins: Pharmacologic profile and product differeritiation
25. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-O-wave myocardial infarction: FRAXIS (FRAxiparine in Ischaemic Syndrome)
26. Long-term low-molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study
27. Low-molecular-weight heparin during instability in coronary artery disease
28. Low-molecular-weight heparin-induced skin necrosis
29. Enoxaparin venous thromboembolic disease treatment study 529 (data on file with Rhone-Poulenc-Rohver.)
30. Use of antithrombotic agents during pregnancy
31. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure
32. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
33. Use of low molecular weight heparin (Enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity
34. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
35. Low-molecular-weight heparin: Biochemistry, pharmacology, and concurrent drug precautions
36. Heparin
37. Heparin administered in the hospital versus heparin administered at home
38. Heparin: Mechanism of action, pharmacokinetics, and limitations
39. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
40. Poor reversal of low molecular weight heparin by protamine
41. Neuraxial block and low molecular weight heparin: Balancing perioperative analgesia and thromboprophylaxis
42. Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty
43. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism
44. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
45. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin
46. Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis
47. Low-molecular-weight heparin for the treatment of acute ischemic stroke
48. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
49. Interaction between the LMWH reviparin and aspirin in healthy volunteers
50. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: Tolerance of a new recombinant hirudin
51. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
52. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban
53. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
54. Treatment of deep venous thrombosis with low-molecular-weight heparins
55. A Comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
56. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
57. Production and chemical processing of low molecular weight heparins
58. New perspectives on the coagulation cascade
59. Economic assessment of low-molecular-weight heparin (Enoxaparin) versus unfractionated heparin in acute coronary syndrome patients results from the ESSENCE randomized trial
60. Low molecular weight heparin in pediatric patients with thrombotic disease: A dose-finding study
61. Delayed onset of anterior tibial compartment syndrome in a patient receiving low-molecular-weight heparin: A case report
62. Cost-effectiveness of enoxaparin vs. low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
63. Delayed-type hypersensitivity to subcutaneous enoxaparin
64. Antithrombotic therapy in children
65. Homozygous protein C deficiency: Description of a new mutation and successful treatment with low molecular weight heparin
66. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
67. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases
68. Economic evaluation of outpatient treatment with low molecular weight heparin for proximal vein thrombosis
69. The effects of renal disease on ardeparin sodium pharmacodynamics
70. Low molecular weight heparin in thrombotic disease in children and adolescents
71. Cost effectiveness of low molecular weight heparin and unfractionated heparin in treatment of deep vein thrombosis
72. Contemporary laboratory monitoring of low molecular weight heparins
73. Safety of low molecular weight heparin in pregnancy: A systematic review
74. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity
75. A Comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
76. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
77. Low molecular weight heparin-induced skin necrosis occurring distant from injection sites without thrombocytopenia
78. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
79. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: An economic evaluation
80. Neutralization of enoxaparin-induced bleeding by protamine sulfate
81. Subcutaneous low molecular weight heparin in place of heparin infusion during warfarin dose optimization in cerebral ischemia
82. A 14-year study of heparin-induced thrombocytopenia
83. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
84. Is there a clinical interaction between low molecular weight heparin and nonsteroidal analgesics after total hip replacement?
85. Low-molecular-weight heparins
86. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin
87. Effect of low-molecular-weight heparin on serum concentrations of potassium
88. Spontaneous suprachoroidal haemorrhage in patient receiving low-molecular-weight heparin (fraxiparin) therapy
89. Adverse skin reactions to low molecular weight heparins: Frequency, management and prevention
90. Issues in developing an outpatient deep venous thrombosis treatment program: University hospital experience